Literature DB >> 17003512

Why can't the immune system control HIV-1? Defining HIV-1-specific CD4+ T cell immunity in order to develop strategies to enhance viral immunity.

Mario A Ostrowski1, Qigui Yu, Feng Yun Yue, Jun Liu, Brad Jones, Xiao X Gu, Mona Loutfy, Colin M Kovacs, Roberta Halpenny.   

Abstract

Globally, at least 60 million people have been infected with the human immunodeficiency virus type 1 (HIV-1), the majority of whom will develop the acquired immunodeficiency syndrome (AIDS) leading to tremendous morbidity and the mortality. Understanding the immunopathogenesis of AIDS and the immune correlates of viral protection are necessary to develop effective vaccines and immunotherapies. A major focus of our laboratory has been to understand the CD4+ T cell immune response directed against HIV- 1, and to determine mechanisms of T cell dysfunction that lead to viral escape. In addition, we are interested in evaluating the TNF-TNFR family members as potential molecular adjuvants that could be incorporated into vaccines which could be used to further boost T cell immunogenicity in healthy or HIV-1-infected individuals, as many of these molecules have been shown to replace the functions of CD4+ T cell help.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17003512     DOI: 10.1385/IR:35:1:89

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  74 in total

1.  Impaired ability of MHC class II-/- dendritic cells to provide tumor protection is rescued by CD40 ligation.

Authors:  I F Hermans; D S Ritchie; A Daish; J Yang; M R Kehry; F Ronchese
Journal:  J Immunol       Date:  1999-07-01       Impact factor: 5.422

2.  HIV induces lymphocyte apoptosis by a p53-initiated, mitochondrial-mediated mechanism.

Authors:  D Genini; D Sheeter; S Rought; J J Zaunders; S A Susin; G Kroemer; D D Richman; D A Carson; J Corbeil; L M Leoni
Journal:  FASEB J       Date:  2000-11-09       Impact factor: 5.191

3.  Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses.

Authors:  I Gramaglia; A D Weinberg; M Lemon; M Croft
Journal:  J Immunol       Date:  1998-12-15       Impact factor: 5.422

4.  Dendritic cells require maturation via CD40 to generate protective antitumor immunity.

Authors:  M F Mackey; J R Gunn; C Maliszewsky; H Kikutani; R J Noelle; R J Barth
Journal:  J Immunol       Date:  1998-09-01       Impact factor: 5.422

5.  Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40.

Authors:  E M Sotomayor; I Borrello; E Tubb; F M Rattis; H Bien; Z Lu; S Fein; S Schoenberger; H I Levitsky
Journal:  Nat Med       Date:  1999-07       Impact factor: 53.440

6.  Simian immunodeficiency virus (SIV) infection of a rhesus macaque induces SIV-specific CD8(+) T cells with a defect in effector function that is reversible on extended interleukin-2 incubation.

Authors:  Y Xiong; M A Luscher; J D Altman; M Hulsey; H L Robinson; M Ostrowski; B H Barber; K S MacDonald
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

7.  Analysis of HIV-1- and CMV-specific memory CD4 T-cell responses during primary and chronic infection.

Authors:  Alexandre Harari; G Paolo Rizzardi; Kim Ellefsen; Donatella Ciuffreda; Patrick Champagne; Pierre-Alexandre Bart; Daniel Kaufmann; Amalio Telenti; Roland Sahli; Giuseppe Tambussi; Laurent Kaiser; Adriano Lazzarin; Luc Perrin; Giuseppe Pantaleo
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

8.  OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors.

Authors:  Y Ohshima; L P Yang; T Uchiyama; Y Tanaka; P Baum; M Sergerie; P Hermann; G Delespesse
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

9.  The role of the p38 mitogen-activated protein kinase, extracellular signal-regulated kinase, and phosphoinositide-3-OH kinase signal transduction pathways in CD40 ligand-induced dendritic cell activation and expansion of virus-specific CD8+ T cell memory responses.

Authors:  Qigui Yu; Colin Kovacs; Feng Yun Yue; Mario A Ostrowski
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

10.  First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes.

Authors:  K L Valentino; M Gutierrez; R Sanchez; M J Winship; D A Shapiro
Journal:  Int J Clin Pharmacol Ther       Date:  2003-10       Impact factor: 1.366

View more
  1 in total

1.  Short communication: Nucleotide variation and positively selected sites in HIV type 1 reverse transcriptase among heterosexual transmission pairs.

Authors:  Uma Shanmugasundaram; Suniti Solomon; Kailapuri G Murugavel; Kumarasamy Nagalingeswaran; Sunil S Solomon; Kenneth H Mayer; Balakrishnan Pachamuthu
Journal:  AIDS Res Hum Retroviruses       Date:  2010-08       Impact factor: 2.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.